Fibrillation auriculaire et anticoagulation chez le patient hémodialysé : une décision difficile

[en] Cardiovascular mortality of hemodialysis patients remains a major problem. The prevalence and incidence of atrial fibrillation in this population are more important than in the general population. The indication of antivitamin K therapy (AVK) in this context of atrial fibrillation must be weighted against the increased risk of bleeding. Unfortunately, and contrary to the general population, an indication of anticoagulation based on embolic or hemorrhagic risk scores is not as clearly established in the hemodialysis population. No prospective randomized study has investigated the benefit/risk balance of anticoagulant treatment in hemodialysis subjects. This article is a review of the current literature on this topic, showing the prevalence of thromboembolic but also bleeding events in the hemodialysis population. The impact of AVK treatment in this specific population is also reviewed. To the best of our knowledge, the indication of treatment must be individualized.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie

BOUQUEGNEAU, Antoine ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie

DUBOIS, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie

SPRYNGER, Muriel ; Centre Hospitalier Universitaire de Liège - CHU > Service de cardiologie

Mariat, C

KRZESINSKI, Jean-Marie ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie

Lancellotti, Patrizio ; Université de Liège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie

Language :

French

Title :

Fibrillation auriculaire et anticoagulation chez le patient hémodialysé : une décision difficile

Publication date :

2017

Journal title :

Néphrologie et Thérapeutique

ISSN :

1769-7255

eISSN :

1872-9177

Publisher :

Elsevier, Paris, France

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 June 2017

Statistics

Number of views

99 (14 by ULiège)

Number of downloads

5 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

[1] Moss, J.D., Cifu, A.S., Management of anticoagulation in patients with atrial fibrillation. JAMA 314 (2015), 291–292.
[2] Singer, D.E., Chang, Y., Fang, M.C., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 151 (2009), 297–305.
[3] Lip, G.Y.H., Lane, D.A., Stroke prevention in atrial fibrillation: a systematic review. JAMA 313 (2015), 1950–1962.
[4] Aguilar, M.I., Hart, R., Pearce, L.A., Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev, 18, 2007, CD006186.
[5] Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
[6] Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
[7] Gage, B.F., van Walraven, C., Pearce, L., Hart, R.G., Koudstaal, P.J., Boode, B.S.P., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110 (2004), 2287–2292.
[8] Olesen, J.B., Lip, G.Y.H., Hansen, M.L., Hansen, P.R., Tolstrup, J.S., Lindhardsen, J., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, 342, 2011, d124.
[9] Agence nationale de sécurité du médicament et des produits de santé (ANSM). Les anticoagulants en France. Études et surveillance. http://ansm.sante.fr/Dossiers/Les-anticoagulants/Les-anticoagulants-en-France-Etudes-et-surveillance/(offset)/0.
[10] Reinecke, H., Engelbertz, C., Schäbitz, W.R., Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke 44 (2013), 2935–2941.
[11] Shen, J.I., Turakhia, M.P., Winkelmayer, W.C., Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?. Curr Opin Nephrol Hypertens 21 (2012), 600–606.
[12] Qamar, A., Bhatt, D.L., Stroke prevention in atrial fibrillation in patients with chronic kidney disease. Circulation 133 (2016), 1512–1515.
[13] De Vriese, A.S., Caluwé, R., Bailleul, E., De Bacquer, D., Borrey, D., Van Vlem, B., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 66 (2015), 91–98.
[14] Speeckaert, M.M., Devreese, K.M., Vanholder, R.C., Dhondt, A., Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients. Nephrol Dial Transplant 28 (2013), 3090–3095.
[15] Harel, Z., Sholzberg, M., Shah, P.S., Pavenski, K., Harel, S., Wald, R., et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 25 (2014), 431–442.
[16] Chan, K.E., Edelman, E.R., Wenger, J.B., Thadhani, R.I., Maddux, F.W., Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131 (2015), 972–979.
[17] Rose, A.J., Hylek, E.M., Ozonoff, A., Ash, A.S., Reisman, J.I., Berlowitz, D.R., Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 8 (2010), 2182–2191.
[18] Limdi, N.A., Beasley, T.M., Baird, M.F., Goldstein, J.A., McGwin, G., Arnett, D.K., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20 (2009), 912–921.
[19] Phelan, P.J., O'Kelly, P., Holian, J., Walshe, J.J., Delany, C., Slaby, J., et al. Warfarin use in hemodialysis patients: what is the risk?. Clin Nephrol 75 (2011), 204–211.
[20] Delanaye, P., Liabeuf, S., Bouquegneau, A., Cavalier, É., Massy, Z., L’éveil de la matrix-gla-protéine sonnera le glas des calcifications vasculaires. Nephrol Ther 11 (2015), 191–200.
[21] Cranenburg, E.C., Schurgers, L.J., Uiterwijk, H.H., Beulens, J.W., Dalmeijer, G.W., Westerhuis, R., et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int 82 (2012), 605–610.
[22] Kaesler, N., Magdeleyns, E., Herfs, M., Schettgen, T., Brandenburg, V., Fliser, D., et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int 86 (2014), 286–293.
[23] Site GPR. Rein. Adaptation posologique. http://sitegpr.com/fr/rein/recherche-par-medicaments/.
[24] Zimmerman, D., Sood, M.M., Rigatto, C., Holden, R.M., Hiremath, S., Clase, C.M., Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 27 (2012), 3816–3822.
[25] Feinberg, W.M., Blackshear, J.L., Laupacis, A., Kronmal, R., Hart, R.G., Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155 (1995), 469–473.
[26] Vázquez, E., Sánchez-Perales, C., Borrego, F., Garcia-Cortés, M.J., Lozano, C., Guzmán, M., et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Hear J 140 (2000), 886–890.
[27] Winkelmayer, W.C., Patrick, A.R., Liu, J., Brookhart, M.A., Setoguchi, S., The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22 (2011), 349–357.
[28] Goldstein, B.A., Arce, C.M., Hlatky, M.A., Turakhia, M., Setoguchi, S., Winkelmayer, W.C., Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 126 (2012), 2293–2301.
[29] Abbott, K.C., Trespalacios, F.C., Taylor, A.J., Agodoa, L.Y., Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol, 4, 2003, 1.
[30] Genovesi, S., Pogliani, D., Faini, A., Valsecchi, M.G., Riva, A., Stefani, F., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46 (2005), 897–902.
[31] Atar, I., Konaş, D., Açikel, S., Külah, E., Atar, A., Bozbaş, H., et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 106 (2006), 47–51.
[32] To, A.C., Yehia, M., Collins, J.F., Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply?. Nephrology 12 (2007), 441–447.
[33] Vazquez, E., Sanchez-Perales, C., Garcia-Garcia, F., Castellano, P., Garcia-Cortes, M.J., Liebana, A., et al. Atrial fibrillation in incident dialysis patients. Kidney Int 76 (2009), 324–330.
[34] Wizemann, V., Tong, L., Satayathum, S., Disney, A., Akiba, T., Fissell, R.B., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77 (2010), 1098–1106.
[35] Wetmore, J.B., Mahnken, J.D., Rigler, S.K., Ellerbeck, E.F., Mukhopadhyay, P., Spertus, J.A., et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 81 (2012), 469–476.
[36] Ansari, N., Manis, T., Feinfeld, D.A., Symptomatic atrial arrhythmias in hemodialysis patients. Ren Fail 23 (2001), 71–76.
[37] Wiesholzer, M., Harm, F., Tomasec, G., Barbieri, G., Putz, D., Balcke, P., Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21 (2001), 35–39.
[38] Knoll, F., Sturm, G., Lamina, C., Zitt, E., Lins, F., Freistätter, O., et al. Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant 27 (2012), 332–337.
[39] Chen, J.J., Lin, L.Y., Yang, Y.H., Hwang, J.J., Chen, P.C., Lin, J.L., Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation – a nation-wide database analyses. Int J Cardiol 177 (2014), 1008–1011.
[40] Genovesi, S., Vincenti, A., Rossi, E., Pogliani, D., Acquistapace, I., Stella, A., et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51 (2008), 255–262.
[41] Chan, K.E., Lazarus, J.M., Thadhani, R., Hakim, R.M., Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 (2009), 2223–2233.
[42] Tanaka, A., Inaguma, D., Shinjo, H., Murata, M., Takeda, A., Presence of atrial fibrillation at the time of dialysis initiation is associated with mortality and cardiovascular events. Nephron 132 (2016), 86–92.
[43] Olesen, J.B., Lip, G.Y.H., Kamper, A.L., Hommel, K., Køber, L., Lane, D.A., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367 (2012), 625–635.
[44] Shah, M., Avgil Tsadok, M., Jackevicius, C.A., Essebag, V., Eisenberg, M.J., Rahme, E., et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129 (2014), 1196–1203.
[45] Winkelmayer, W.C., Liu, J., Setoguchi, S., Choudhry, N.K., Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6 (2011), 2662–2668.
[46] Shen, J.I., Montez-Rath, M.E., Lenihan, C.R., Turakhia, M.P., Chang, T.I., Winkelmayer, W.C., Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66 (2015), 677–688.
[47] Jassal, S.V., Coulshed, S.J., Douglas, J.F., Stout, R.W., Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Am J Kidney Dis 30 (1997), 219–223.
[48] Sood, M.M., Larkina, M., Thumma, J.R., Tentori, F., Gillespie, B.W., Fukuhara, S., et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 84 (2013), 600–608.
[49] Wetmore, J.B., Ellerbeck, E.F., Mahnken, J.D., Phadnis, M., Rigler, S.K., Mukhopadhyay, P., et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann Epidemiol 2 (2013), 112–118.
[50] Shih, C.J., Ou, S.M., Chao, P.W., Kuo, S.C., Lee, Y.J., Yang, C.Y., et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 133 (2016), 265–272.
[51] Vázquez, E., Sánchez-Perales, C., García-Cortes, M.J., Borrego, F., Lozano, C., Guzmán, M., et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol 87 (2003), 135–139.
[52] Lai, H.M., Aronow, W.S., Kalen, P., Adapa, S., Patel, K., Goel, A., et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renov Dis 2 (2009), 33–37.
[53] Chou, C.Y., Kuo, H.L., Wang, S.M., Liu, J.H., Lin, H.H., Liu, Y.L., et al. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol Dial Transplant 25 (2010), 1225–1230.
[54] Wakasugi, M., Kazama, J.J., Tokumoto, A., Suzuki, K., Kageyama, S., Ohya, K., et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol 18 (2014), 662–669.
[55] Labriola, L., Jadoul, M., Sailing between Scylla and Charybdis: the high serum K-low dialysate K quandary. Semin Dial 27 (2014), 463–471.
[56] Iseki, K., Kinjo, K., Kimura, Y., Osawa, A., Fukiyama, K., Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 44 (1993), 1086–1090.
[57] Holden, R.M., Clase, C.M., Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial 22 (2009), 503–511.
[58] Holden, R.M., Harman, G.J., Wang, M., Holland, D., Day, A.G., Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008), 105–110.
[59] Yang, J.Y., Lee, T.C., Montez-Rath, M.E., Paik, J., Chertow, G.M., Desai, M., et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 23 (2012), 495–506.
[60] Luo, J.C., Leu, H.B., Huang, K.W., Huang, C.C., Hou, M.C., Lin, H.C., et al. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ 183 (2011), E1345–E1351.
[61] Wu, C.Y., Wu, M.S., Kuo, K.N., Wang, C.B., Chen, Y.J., Lin, J.T., Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut 60 (2011), 1038–1042.
[62] Sohal, A.S., Gangji, A.S., Crowther, M.A., Treleaven, D., Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 118 (2006), 417–422.
[63] Chachati, A., Godon, J.P., Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transplant 1 (1987), 233–237.
[64] Elliott, M.J., Zimmerman, D., Holden, R.M., Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 50 (2007), 433–440.
[65] Biggers, J.A., Remmers, A.R., Glassford, D.M., Sarles, H.E., Lindley, J.D., Fish, J.C., The risk of anticoagulation in hemodialysis patients. Nephron 18 (1977), 109–113.
[66] O'shea, S.I., Lawson, J.H., Reddan, D., Murphy, M., Ortel, T.L., Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38 (2003), 541–548.
[67] LeSar, C.J., Merrick, H.W., Smith, M.R., Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 189 (1999), 73–79.
[68] Crowther, M.A., Clase, C.M., Margetts, P.J., Julian, J., Lambert, K., Sneath, D., et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 13 (2002), 2331–2337.
[69] Zellweger, M., Bouchard, J., Raymond-Carrier, S., Laforest-Renald, A., Quérin, S., Madore, F., Systemic anticoagulation and prevention of hemodialysis catheter malfunction. ASAIO J 51 (2005), 360–365.
[70] Mokrzycki, M.H., Jean-Jerome, K., Rush, H., Zdunek, M.P., Rosenberg, S.O., A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59 (2001), 1935–1942.
[71] Traynor, J.P., Walbaum, D., Woo, Y.M., Teenan, P., Fox, J.G., Mactier, R.A., Low-dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrol Dial Transplant, 16, 2001, 645.
[72] Seliger, S.L., Gillen, D.L., Longstreth, W.T., Kestenbaum, B., Stehman-Breen, C.O., Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 64 (2003), 603–609.
[73] Seliger, S.L., Gillen, D.L., Tirschwell, D., Wasse, H., Kestenbaum, B.R., Stehman-Breen, C.O., Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 14 (2003), 2623–2631.
[74] Murray, A.M., Seliger, S., Lakshminarayan, K., Herzog, C.A., Solid, C.A., Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol 24 (2013), 1166–1173.
[75] Krüger, T., Brandenburg, V., Schlieper, G., Marx, N., Floege, J., Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant 28 (2013), 534–541.
[76] Khalid, F., Qureshi, W., Qureshi, S., Alirhayim, Z., Garikapati, K., Patsias, I., Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Ren Fail 35 (2013), 1228–1235.
[77] Bonde, A.N., Lip, G.Y.H., Kamper, A.L., Hansen, P.R., Lamberts, M., Hommel, K., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64 (2014), 2471–2482.
[78] Clase, C.M., Holden, R.M., Sood, M.M., Rigatto, C., Moist, L.M., Thomson, B.K.A., et al. Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?. Nephrol Dial Transplant 27 (2012), 3719–3724.
[79] Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 17, 2015, euv309.
[80] Macle, L., Cairns, J.A., Andrade, J.G., Mitchell, L.B., Nattel, S., Verma, A., The 2014 atrial fibrillation guidelines companion: a practical approach to the use of the Canadian Cardiovascular Society guidelines. Can J Cardiol 31 (2015), 1207–1218.
[81] Herzog, C.A., Asinger, R.W., Berger, A.K., Charytan, D.M., Díez, J., Hart, R.G., et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 80 (2011), 572–586.
[82] Li, J., Wang, L., Hu, J., Xu, G., Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis 25 (2015), 706–713.
[83] Liu, G., Long, M., Hu, X., Hu, C.H., Liao, X.X., Du, Z.M., et al. Effectiveness and safety of warfarin in dialysis patients with atrial fibrillation: a meta-analysis of observational studies. Medicine (Baltimore), 94, 2015, e2233.
[84] Lee, M., Saver, J.L., Hong, K.S., Wu, Y.L., Huang, W.H., Rao, N.M., et al. Warfarin use and risk of stroke in patients with atrial fibrillation undergoing hemodialysis: a meta-analysis. Medicine (Baltimore), 95, 2016, e2741.
[85] Dahal, K., Kunwar, S., Rijal, J., Schulman, P., Lee, J., Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 149 (2016), 951–959.
[86] Nochaiwong, S., Ruengorn, C., Awiphan, R., Dandecha, P., Noppakun, K., Phrommintikul, A., Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart, 3, 2016, e000441.
[87] Bennis, Y., Vengadessane, S., Bodeau, S., Gras, V., Bricca, G., Kamel, S., et al. Les calcifications vasculaires sous anti-vitamines K: un effet indésirable méconnu. Therapie 71 (2016), 355–363.
[88] Moe, S.M., Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36:Suppl. 2 (2006), 51–62.
[89] Evrard, S., Delanaye, P., Kamel, S., Cristol, J.P., Cavalier, E., Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 438 (2015), 401–414.
[90] Price, P.A., Faus, S.A., Williamson, M.K., Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arter Thromb Vasc Biol 18 (1998), 1400–1407.
[91] Delanaye, P., Krzesinski, J.M.M., Warling, X., Moonen, M., Smelten, N., Médart, L., et al. Dephosphorylated-uncarboxylated matrix gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol, 15, 2014, 145.
[92] Schlieper, G., Westenfeld, R., Kruger, T., Cranenburg, E.C., Magdeleyns, E.J., Brandenburg, V.M., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 22 (2011), 387–395.
[93] Brandenburg, V.M., Kramann, R., Rothe, H., Kaesler, N., Korbiel, J., Specht, P., et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant, 2016, 10.1093/ndt/gfv438.
[94] Hayashi, M., Takamatsu, I., Kanno, Y., Yoshida, T., Abe, T., Sato, Y., A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27 (2012), 1580–1584.
[95] Nigwekar, S.U., Zhao, S., Wenger, J., Hymes, J.L., Maddux, F.W., Thadhani, R.I., et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol 27 (2016), 3421–3429.
[96] Voroneanu, L., Ortiz, A., Nistor, I., Covic, A., Atrial fibrillation in CKD. Eur J Intern Med 33 (2016), 3–13.
[97] De Vriese, A.S., Caluwé, R., Raggi, P., The atrial fibrillation conundrum in dialysis patients. Am Heart J 174 (2016), 111–119.
[98] Schlieper, G., Floege, J., Challenging the use of warfarin in patients on dialysis with atrial fibrillation. Nat Rev Nephrol, 11, 2015, 450.
[99] Thet, Z., Vilayur, E., Atrial fibrillation and warfarin use in haemodialysis patients: an individualized holistic approach is important in stroke prevention. Nephrol 18 (2013), 331–339.
[100] Kessler, M., Moureau, F., Nguyen, P., Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Semin Dial 28 (2015), 474–489.
[101] Devereaux, P.J., Anderson, D.R., Gardner, M.J., Putnam, W., Flowerdew, G.J., Brownell, B.F., et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323 (2001), 1218–1222.